Germany GKV Medical Device Procurement: Statutory Health Insurance, G-DRG Hospital Reimbursement & Market Access Guide (2026)

Why Understanding German Medical Device Procurement Matters

Germany is the largest medical device market in Europe and the third-largest worldwide, after the United States and China. The German medical device market accounts for roughly EUR 35 billion (~USD 38 billion) in annual revenue (2025 estimate), representing approximately 25% of the total European market — significantly outpacing the United Kingdom, France, and Italy. The in vitro diagnostics (IVD) market was valued at approximately EUR 3.5 billion (~USD 3.8 billion) in 2024, with projected growth at a 1.9% CAGR through 2030.

Approximately 90% of Germany's 84 million residents are covered by statutory health insurance (Gesetzliche Krankenversicherung, or GKV), making it the dominant payer for medical device procurement. An additional 11% are covered by private health insurance (Private Krankenversicherung, or PKV). Understanding how the GKV system procures and reimburses medical devices is essential for any manufacturer seeking to access Europe's largest healthcare market.

This guide covers the full landscape: how hospitals procure devices through the G-DRG system, how innovative products gain reimbursement via the NUB pathway, how outpatient medical aids are listed in the Hilfsmittelverzeichnis, and what foreign manufacturers must do to compete in the German public-sector supply chain.

The German Medical Device Procurement Ecosystem

Overview of Procurement Channels

Medical devices reach German end-users through three primary channels:

Channel	Share of Medical Device Purchasing	Key Actors
Hospital direct procurement	~55–60% (inpatient DRG-bundled)	~1,900 hospitals, university medical centers
GPO / group purchasing	~25–30% of hospital supply spend	~10 national GPOs (e.g., EKONO, Gauting, H+H)
Outpatient statutory insurance	~10–15% (Hilfsmittel, DiGA, EBM)	GKV-Spitzenverband, G-BA, 73 sickness funds

Key Market Data

Metric	Value
German medical device market (annual)	~EUR 35 billion (~USD 38 billion)
Medical device manufacturing industry (2024)	EUR 46 billion (production value)
Number of medical device manufacturers	~1,500 (with 20+ employees)
Population covered by GKV	~90% (~75 million people)
Number of GKV sickness funds	~93
Number of hospitals	~1,900
IVD market (2024)	~EUR 3.5 billion (~USD 3.8 billion)
GKV healthcare expenditure (2025)	~EUR 300 billion

Regulatory Foundations: BfArM and MDR

BfArM (Federal Institute for Drugs and Medical Devices)

The Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) is the main federal authority responsible for medical device oversight in Germany. BfArM does not perform conformity assessments (that is the role of Notified Bodies under EU MDR), but it has critical responsibilities in:

• Market surveillance and vigilance — Tracking adverse events and field corrective actions
• Qualification and classification — Determining whether a product qualifies as a medical device
• Clinical investigation oversight — Approving or being notified of clinical studies conducted in Germany
• DiGA pathway — Evaluating and listing Digital Health Applications in the DiGA directory
• DMIDS database — Operating the German Medical Devices Information and Database System

CE Marking Under EU MDR

All medical devices placed on the German market must carry CE marking under the EU Medical Device Regulation (MDR 2017/745) or IVD Regulation (IVDR 2017/746). Germany also requires registration with the relevant federal state authority (Landesbehörde) when first placing a device on the market. This is a prerequisite for any procurement or reimbursement activity.

Hospital Procurement: The G-DRG System

How Hospitals Are Paid

Germany reimburses hospitals through the German Diagnosis-Related Groups (G-DRG) system, a case-based flat-rate payment mechanism managed by the Institute for the Hospital Remuneration System (InEK). Under G-DRG:

• All costs related to treatment and hospitalization, including medical devices, are bundled into a single DRG payment per case
• Each DRG compensation amount is based on empirical cost data collected from hundreds of German clinics
• The system is revised annually by InEK

This means that for most medical devices used in hospitals, there is no separate reimbursement — the device cost is absorbed within the DRG case rate. Hospitals therefore have a strong incentive to procure devices at the lowest possible cost, which drives aggressive price negotiation with manufacturers.

The 2026 DRG Update

The 2026 DRG catalog, published in November 2025, introduced:

• 5 new DRGs in diagnostic imaging, men's health, nephrology and urology, and radiotherapy
• 13 new ZE (Zusatzentgelt) categories — additional reimbursement categories primarily for drugs
• A DRG inflator of 5.17% for 2026, a key parameter determining reimbursement price increases

Hybrid-DRGs: The Shift to Ambulatory Care

A major structural reform is the expansion of Hybrid-DRGs, which provide the same reimbursement whether a procedure is performed inpatient or outpatient. In 2026, the Hybrid-DRG catalog expanded from 22 to 69 distinct Hybrid-DRGs, covering approximately 904 OPS procedure codes. For the first time, cases with up to two overnight stays are eligible for hybrid reimbursement.

Policy targets for Hybrid-DRG adoption:

• ~1 million cases in 2026
• ~1.5 million by 2028
• ~2 million by 2030

This shift means manufacturers must consider ambulatory pricing strategies alongside traditional hospital pricing.

Innovative Device Reimbursement: The NUB Pathway

What Is NUB?

The Neue Untersuchungs- und Behandlungsmethoden (NUB) mechanism is the primary gateway for introducing innovative medical devices into the German inpatient reimbursement system. Without NUB status, a new device may be assigned to an existing DRG that does not adequately cover its cost.

How the NUB Process Works

1. Hospital application (October–January) — Hospitals submit NUB requests to InEK describing the innovative method, the device, and the expected cost impact
2. InEK evaluation — InEK assesses whether the method is truly innovative and not yet adequately represented in the DRG system
3. Status assignment (February–March) — InEK assigns one of four statuses:
   • Status 1: Method qualifies for supplemental reimbursement (positive)
   • Status 2: Insufficient data to evaluate
   • Status 3: Method already covered by existing DRGs
   • Status 4: Method does not meet criteria
4. Hospital-sickness fund negotiation — Hospitals with Status 1 negotiate supplemental payments with their regional sickness funds
5. DRG integration (longer term) — Successful NUB methods may eventually be integrated into the regular DRG catalog

NUB Statistics

The NUB process is highly competitive. In the 2025 results, out of 1,025 submitted technologies, approximately 29% received a positive Status 1. This underscores the importance of a well-prepared reimbursement strategy that is technically and economically sound.

Strategic Recommendations for NUB

• Engage early with 5–10 German hospitals that are opinion leaders in your therapeutic area
• Provide economic models demonstrating cost impact and clinical benefit
• Support multiple hospital applications — more applications increase the likelihood of positive status
• Plan for 12–18 months from initial engagement to first reimbursement

Outpatient Medical Aids: The Hilfsmittelverzeichnis

What Is the Hilfsmittelverzeichnis?

Medical devices used at home — such as hearing aids, surgical stockings, orthopedic insoles, wheelchairs, and diabetes supplies — are reimbursed under GKV through the Catalog of Assistive Devices (Hilfsmittelverzeichnis). This directory is managed by the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds).

Once a device is approved and listed in the Hilfsmittelverzeichnis, it can be reimbursed by all statutory health insurance funds. The assessment criteria include:

• Therapeutic benefit — Does the device provide a demonstrable health benefit?
• Cost-effectiveness — Is the device economically efficient compared to alternatives?
• Necessity for patient care — Is the device medically necessary?

Application Process

1. Manufacturer submits application to GKV-Spitzenverband
2. Assessment by GKV-Spitzenverband, with BfArM involvement for higher-risk devices
3. Review focuses on therapeutic benefit, cost-effectiveness, and care necessity
4. If approved, the device is listed with a fixed reimbursement amount
5. Processing time ranges from several months to over a year depending on complexity

Digital Health Applications: DiGA

The DiGA Fast-Track Pathway

Germany pioneered the DiGA (Digitale Gesundheitsanwendungen) pathway, which allows digital health applications to be listed in a dedicated directory and reimbursed by statutory health insurance. Key features:

• Eligibility: Software-based medical devices in Class I or IIa (expanding to include certain Class IIb devices from 2026)
• Fast-track process: Application to BfArM, with listing in the DiGA directory upon demonstrating positive healthcare effects
• Pricing: Manufacturers propose a price; BfArM evaluates evidence; from 2026, contracts must include performance-based pricing components
• Duration: Initial 12-month listing with provisional reimbursement, then evidence-based price negotiation for permanent listing

DiGA represents a significant opportunity for digital health companies, as it provides a structured reimbursement pathway that does not exist in most other countries.

GPO Group Purchasing Organizations

The Role of GPOs in Germany

Unlike the United States, where GPOs dominate hospital purchasing, German GPOs operate in a more decentralized environment. Approximately 10 national GPOs aggregate purchasing power for groups of hospitals. Key organizations include:

GPO	Focus
Prospitalia	One of Germany's largest hospital GPOs — broad product portfolio
Clinicpartner	Hospital supplies, medical technology, consumables
Agkamed	Medical devices and pharmaceuticals
EKONO	Hospital supplies, pharmaceuticals
UNICO	Multi-hospital procurement network
Klinikeinkauf NRW	Regional hospital purchasing consortium

Approximately 80% of German hospitals use GPOs to procure hospital products. GPOs have significantly greater bargaining power than any single hospital when negotiating with medical device manufacturers, and their influence has increased substantially over the past decade.

How GPO Contracting Works

1. Tender issuance — The GPO issues a tender for a product category across member hospitals
2. Manufacturer bidding — Manufacturers submit bids with pricing and product specifications
3. Evaluation and award — The GPO evaluates bids based on price, quality, supply reliability, and innovation
4. Framework agreement — A 1–3 year contract is awarded, typically to one or two suppliers per category
5. Hospital ordering — Individual hospitals place orders against the framework agreement

Importantly, purchasing decisions are ultimately made by each individual hospital. GPO contracts are not legally binding on member hospitals — they provide preferred pricing and terms, but hospitals can choose to procure outside the GPO framework.

Hospital Tendering and Procurement Practices

Direct Hospital Procurement

Many German hospitals, particularly large university medical centers, conduct their own procurement:

• Public tenders above EU thresholds are published in the Supplement to the Official Journal of the EU (TED/Tenders Electronic Daily)
• National tenders below EU thresholds are published on German procurement portals (e.g., Bund.de, VERGABE24)
• Direct negotiations may be used for smaller purchases below threshold values

Lead Buyer Arrangements

Hospitals may also form lead buyer arrangements, where one hospital procures on behalf of a group. This is increasingly common among hospital chains and municipal hospital networks. Manufacturers should identify and build relationships with lead buyers who influence procurement across multiple facilities.

Pricing and Reimbursement Mechanisms

Pharmaceutical Pricing: AMNOG (Reference Only)

While pharmaceutical pricing in Germany operates under the AMNOG (Arzneimittelmarkt-Neuordnungsgesetz) process, medical devices follow a fundamentally different pathway. However, understanding AMNOG is relevant because:

• The GKV-Finanzstabilisierungsgesetz (GKV-FinStG) of 2022 extended the pharmaceutical price freeze until December 31, 2026
• The Medical Research Law 2024 introduced provisions for confidential reimbursement amounts (temporary until mid-2028)
• These policy tools signal the government's broader approach to healthcare cost containment, which also affects device procurement

Medical Device Pricing

For medical devices, pricing is determined through several mechanisms:

Setting	Pricing Mechanism	Key Actor
Inpatient (hospital)	Bundled in G-DRG case rate	InEK, hospitals
Inpatient (innovative)	NUB supplemental payment	InEK, sickness funds
Outpatient (medical aids)	Hilfsmittelverzeichnis fixed amounts	GKV-Spitzenverband
Outpatient (digital health)	DiGA manufacturer-proposed price	BfArM
Outpatient (procedures)	EBM fee schedule	G-BA, sickness funds
Outpatient (new methods)	Selective contracts	Individual sickness funds

The G-BA (Gemeinsamer Bundesausschuss)

The Joint Federal Committee (G-BA) is the central decision-making body for statutory insurance. It decides which treatment methods and devices are included in outpatient reimbursement lists. Approval requires demonstrating:

• Clinical benefit
• Safety and performance
• In some cases, cost-effectiveness

Without G-BA approval, devices cannot be billed under statutory insurance in outpatient care. This is governed by the principle of Erlaubnisvorbehalt: if a method is not explicitly approved, it cannot be reimbursed.

Requirements for Foreign Manufacturers

Regulatory Requirements

1. CE marking under MDR/IVDR — Mandatory for all medical devices
2. European Authorized Representative (EC REP) — Required for non-EU manufacturers
3. Registration with federal state authority — First placing on the German market must be registered
4. BfArM notification — For clinical investigations and certain device categories
5. EUDAMED registration — Actor registration and device registration in the European database

Market Access Requirements

1. Reimbursement strategy — Determine which pathway applies (G-DRG, NUB, Hilfsmittelverzeichnis, DiGA, selective contract)
2. Hospital engagement — Build relationships with key opinion leaders and procurement departments
3. GPO participation — Register with relevant GPOs and respond to tenders
4. German-language documentation — Product information, IFU, and labeling must be in German
5. Local presence — Consider establishing a German subsidiary or partnering with a distributor who understands the reimbursement landscape

Practical Tips for Market Entry

• Start with NUB: For innovative devices, the NUB pathway provides the fastest route to meaningful reimbursement. Engage with 5–10 German hospitals before launching.
• Target university hospitals: Germany's 38 university medical centers are the most active adopters of new technology and the most likely to submit NUB applications.
• Price competitively: German hospitals are under significant cost pressure and will aggressively negotiate. Be prepared with economic models demonstrating value.
• Consider selective contracts: For devices that don't fit the standard reimbursement pathways, negotiate directly with individual sickness funds for selective contracts.
• Plan for the Hybrid-DRG transition: As Germany shifts more procedures to ambulatory settings, ensure your pricing strategy accounts for both inpatient and outpatient reimbursement.

Key Government Agencies and Organizations

Organization	Role
BfArM	Medical device regulation, DiGA, market surveillance
GKV-Spitzenverband	National association of statutory health insurance funds
InEK	Hospital remuneration system (G-DRG)
G-BA	Joint Federal Committee — decides outpatient coverage
Federal Ministry of Health (BMG)	Overall health policy and legislation
Federal state authorities (Landesbehörden)	Market surveillance, device registration
Notified Bodies	MDR/IVDR conformity assessment

Summary: Navigating the German Market

Germany offers the largest medical device market in Europe, but accessing it requires understanding a multi-layered reimbursement and procurement system:

1. Hospital devices are reimbursed through bundled G-DRG payments — manufacturers must navigate NUB or await DRG recoding
2. Outpatient medical aids require listing in the Hilfsmittelverzeichnis managed by GKV-Spitzenverband
3. Digital health products have a dedicated fast-track pathway through DiGA
4. GPOs provide aggregated procurement but cannot mandate hospital purchasing decisions
5. The Hybrid-DRG reform is shifting the landscape toward ambulatory care, creating new pricing and access considerations

For foreign manufacturers, success in Germany requires early reimbursement planning, strong hospital relationships, competitive pricing, and a clear understanding of which pathway — NUB, Hilfsmittelverzeichnis, DiGA, or selective contracts — is most appropriate for their product.